CN112351778B - 稠合三环杂环类化合物及其治疗用途 - Google Patents
稠合三环杂环类化合物及其治疗用途 Download PDFInfo
- Publication number
- CN112351778B CN112351778B CN201980043105.6A CN201980043105A CN112351778B CN 112351778 B CN112351778 B CN 112351778B CN 201980043105 A CN201980043105 A CN 201980043105A CN 112351778 B CN112351778 B CN 112351778B
- Authority
- CN
- China
- Prior art keywords
- group
- alkyl
- cycloalkyl
- aryl
- heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862691208P | 2018-06-28 | 2018-06-28 | |
| US62/691,208 | 2018-06-28 | ||
| PCT/US2019/039860 WO2020006432A1 (en) | 2018-06-28 | 2019-06-28 | Fused tricyclic heterocycle compounds and therapeutic uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112351778A CN112351778A (zh) | 2021-02-09 |
| CN112351778B true CN112351778B (zh) | 2023-04-04 |
Family
ID=68987618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980043105.6A Active CN112351778B (zh) | 2018-06-28 | 2019-06-28 | 稠合三环杂环类化合物及其治疗用途 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11535633B2 (enExample) |
| EP (1) | EP3813827A4 (enExample) |
| JP (1) | JP2021530442A (enExample) |
| KR (1) | KR20210025016A (enExample) |
| CN (1) | CN112351778B (enExample) |
| TW (1) | TW202019408A (enExample) |
| WO (1) | WO2020006432A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3802534B1 (en) | 2018-05-25 | 2022-07-13 | Incyte Corporation | Tricyclic heterocyclic compounds as sting activators |
| US10875872B2 (en) | 2018-07-31 | 2020-12-29 | Incyte Corporation | Heteroaryl amide compounds as sting activators |
| WO2020028565A1 (en) | 2018-07-31 | 2020-02-06 | Incyte Corporation | Tricyclic heteraryl compounds as sting activators |
| AU2019326633B2 (en) * | 2018-08-24 | 2022-09-08 | Adlai Nortye Biopharma Co., Ltd. | High activity sting protein agonist |
| CA3110474C (en) * | 2018-08-29 | 2024-04-23 | Adlai Nortye Biopharma Co., Ltd. | Highly active sting protein agonist compound |
| US11596692B1 (en) | 2018-11-21 | 2023-03-07 | Incyte Corporation | PD-L1/STING conjugates and methods of use |
| CN113195473B (zh) * | 2018-12-14 | 2022-11-22 | 江苏恒瑞医药股份有限公司 | 三环化合物作为sting激动剂及其制备方法和医药用途 |
| WO2020146237A1 (en) | 2019-01-07 | 2020-07-16 | Incyte Corporation | Heteroaryl amide compounds as sting activators |
| KR20220056176A (ko) | 2019-08-02 | 2022-05-04 | 메르사나 테라퓨틱스, 인코포레이티드 | 암 치료를 위한 sting(인터페론 유전자의 자극인자) 작용제로서의 비스-[n-((5-카바모일)-1h-벤조[d]이미다졸-2-일)-피라졸-5-카복사미드] 유도체 및 관련 화합물 |
| CN116196435B (zh) | 2020-04-02 | 2025-12-02 | 梅尔莎纳医疗公司 | 包含sting激动剂的抗体药物缀合物 |
| US20230141284A1 (en) | 2020-04-10 | 2023-05-11 | Ono Pharmaceutical Co., Ltd. | Cancer therapeutic method |
| CN115554303B (zh) * | 2021-09-18 | 2024-07-09 | 上海科技大学 | 一种三环类化合物、其制备方法及其应用 |
| WO2023158862A2 (en) * | 2022-02-21 | 2023-08-24 | Geode Therapeutics Inc. | Stimulator of interferon genes (sting) modulators, and compositions and methods thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2731708B1 (fr) * | 1995-03-13 | 1997-04-30 | Synthelabo | Derives de piperidine, leur procede de preparation et leur application en therapeutique |
| FR2747678B1 (fr) * | 1996-04-22 | 1998-05-22 | Synthelabo | Composes derives d'imidazobenzoxazine, leurs procedes de preparation et leurs utilisations en therapeutique |
| CA2332239A1 (en) * | 1998-05-15 | 1999-11-25 | Guilford Pharmaceuticals Inc. | Fused tricyclic compounds which inhibit parp activity |
| ECSP003637A (es) | 1999-08-31 | 2002-03-25 | Agouron Pharma | Inhibidores triciclicos de poli (adp-ribosa) polimerasas |
| CA2324090A1 (en) | 1999-10-25 | 2001-04-25 | Leviton Manufacturing Co., Inc. | Electrical wiring device with multiple types of wire terminations |
| MX2008001152A (es) * | 2005-08-05 | 2008-04-02 | Astrazeneca Ab | Benzimidazoles triciclicos y su uso como moduladores del receptor de glutamato metabotropico. |
| EP2324044A4 (en) | 2008-08-04 | 2012-04-25 | Univ Miami | STING (STIMULATOR OF INTERFERON GENES) AS A REGULATOR OF BORROWING IMMUNE REACTIONS |
| US8653089B2 (en) * | 2011-02-09 | 2014-02-18 | F. Hoffmann-La Roche Ag | Heterocyclic compounds and methods of use |
| AU2013256468A1 (en) | 2012-04-30 | 2014-12-04 | Glen N. Barber | Modulating immune responses |
| JP6599979B2 (ja) * | 2014-09-15 | 2019-10-30 | インサイト・コーポレイション | Ｂｅｔタンパク質阻害剤として用いるための三環式複素環化合物 |
| SG10201900628RA (en) | 2016-04-07 | 2019-02-27 | Glaxosmithkline Ip Dev Ltd | Heterocyclic amides useful as protein modulators |
| WO2017175156A1 (en) * | 2016-04-07 | 2017-10-12 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides useful as protein modulators |
-
2019
- 2019-06-28 CN CN201980043105.6A patent/CN112351778B/zh active Active
- 2019-06-28 WO PCT/US2019/039860 patent/WO2020006432A1/en not_active Ceased
- 2019-06-28 US US17/255,712 patent/US11535633B2/en active Active
- 2019-06-28 JP JP2020570791A patent/JP2021530442A/ja active Pending
- 2019-06-28 KR KR1020207037227A patent/KR20210025016A/ko not_active Ceased
- 2019-06-28 TW TW108123007A patent/TW202019408A/zh unknown
- 2019-06-28 EP EP19825637.2A patent/EP3813827A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP3813827A1 (en) | 2021-05-05 |
| TW202019408A (zh) | 2020-06-01 |
| US20210300944A1 (en) | 2021-09-30 |
| US11535633B2 (en) | 2022-12-27 |
| KR20210025016A (ko) | 2021-03-08 |
| EP3813827A4 (en) | 2022-04-13 |
| WO2020006432A1 (en) | 2020-01-02 |
| CN112351778A (zh) | 2021-02-09 |
| JP2021530442A (ja) | 2021-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112351778A (zh) | 稠合三环杂环类化合物及其治疗用途 | |
| JP4866722B2 (ja) | 縮合ｎ−ヘテロサイクリック化合物およびｃｒｆ受容体アンタゴニストとしてのその使用 | |
| CN113637005A (zh) | 用于癌症治疗的kras抑制剂 | |
| CN111094289B (zh) | 吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用 | |
| WO2023274251A1 (zh) | 一类抑制rna解旋酶dhx33的多环化合物及其应用 | |
| JP2016501203A (ja) | インドールアミン２，３−ジオキシゲナーゼの阻害剤として有用な化合物 | |
| IL301225A (en) | Heterocyclic compounds as CBP/EP300 bromodomain inhibitors | |
| JP2006515334A (ja) | ＣＲＦ受容体アンタゴニストとしてのヘテロアリール置換ピロロ［２，３−ｂ］ピリジン誘導体 | |
| TW202007687A (zh) | 經進一步取代之三唑并喹噁啉衍生物 | |
| CN110494431B (zh) | 氮杂环类衍生物、其制备方法及其医药用途 | |
| JP2023520595A (ja) | ピラゾロピリダジノン化合物、その医薬組成物及びその用途 | |
| WO2022111636A1 (zh) | 稠合三环化合物、其制备方法及其在医药上的应用 | |
| WO2023179567A1 (zh) | 作为Toll样受体激动剂的嘧啶并哒嗪酮类化合物 | |
| WO2018171611A1 (zh) | 6-吡唑-[1,2,4]三唑并[4,3-a]吡啶-3-酰胺类衍生物、其制备方法及其在医药上的应用 | |
| CN113195473B (zh) | 三环化合物作为sting激动剂及其制备方法和医药用途 | |
| CN115362155B (zh) | 芳胺类衍生物及其制备方法和医药用途 | |
| CN103958526B (zh) | 嘧啶二胺类衍生物、其制备方法及其在医药上的应用 | |
| CN112574212B (zh) | 一种嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用 | |
| CN109232533A (zh) | 氮杂环类衍生物、其制备方法及其医药用途 | |
| CN111433201B (zh) | 苯并氮杂䓬衍生物、其制备方法及其在医药上的应用 | |
| JP7729632B2 (ja) | 新規三環芳香族複素環化合物、ならびにその調製方法、医薬組成物および適用 | |
| TWI894448B (zh) | Ctla-4小分子降解劑及其應用 | |
| HK40045549A (en) | Fused tricyclic heterocycle compounds and therapeutic uses thereof | |
| CN111825694A (zh) | 稠环化合物、其制备方法及用途 | |
| HUP0400460A2 (hu) | Kortikotropin-feloldó faktor (CRF) receptor antagonista triciklusos vegyületek és ezeket tartalmazó gyógyszerkészítmények |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40045549 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |